Ruxolitinib karamin kwayoyin Janus kinase inhibitor ne wanda ake amfani dashi a cikin maganin tsaka-tsaki ko babban haɗari myelofibrosis da nau'ikan juriya na polycythemia vera da graft-vs-host cuta. Ruxolitinib yana da alaƙa da ɗan gajeren lokaci kuma yawanci mai sauƙi a cikin maganin aminotransferase yayin jiyya da kuma wasu lokuta marasa iyaka na iyakantaccen rauni, raunin hanta a asibiti da kuma lokuta na sake kunna hanta na hepatitis B a cikin mutane masu saukin kamuwa.

Ruxolitinib shine mai hana Janus-associated kinase (JAK) mai hanawa tare da yuwuwar ayyukan antineoplastic da immunomodulating. Ruxolitinib musamman yana ɗaure kuma yana hana furotintyrosinekinases JAK 1 da 2, wanda zai iya haifar da raguwa a cikin kumburi da kuma hana yaduwar salula. Hanyar JAK-STAT (mai canza siginar sigina da mai kunnawa na rubutu) hanya tana taka muhimmiyar rawa a cikin siginar siginar cytokines da yawa da abubuwan haɓaka kuma suna shiga cikin haɓakar salon salula, haɓaka, hematopoiesis, da amsawar rigakafi; JAK kinases na iya haɓakawa a cikin cututtukan kumburi, cututtuka na myeloproliferative, da kuma malignancies daban-daban.

Ruxolitinib apyrazolewanda aka maye gurbinsa a matsayi na 1 ta ƙungiyar 2-cyano-1-cyclopentylethyl kuma a matsayi na 3 ta ƙungiyar pyrrolo [2,3-d] pyrimidin-4-yl. An yi amfani da shi azaman gishirin phosphate don kula da marasa lafiya tare da tsaka-tsaki ko babban haɗari na myelofibrosis, ciki har da myelofibrosis na farko, post-polycythemia vera myelofibrosis da post-mahimmancin thrombocythemia myelofibrosis. Yana da matsayi a matsayin wakili na antineoplastic da EC 2.7.10.2 (protein na musamman-tyrosinekinase) inhibitor. Nitrile ne, apyrrolopyrimidinekuma memba na pyrazoles.